Identification of β-Lactams Active against <i>Mycobacterium tuberculosis</i> by a Consortium of Pharmaceutical Companies and Academic Institutions.

Authors:
Gold B; Zhang J; Quezada LL; Roberts J; Ling Y and 39 more

Journal:
ACS Infect Dis

Publication Year: 2022

DOI:
10.1021/acsinfecdis.1c00570

PMCID:
PMC8922279

PMID:
35192346

Journal Information

Full Title: ACS Infect Dis

Abbreviation: ACS Infect Dis

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Anti-Infective Agents

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"The authors declare no competing financial interest."

Evidence found in paper:

"This work was supported by the TB Drug Accelerator Program of the Bill & Melinda Gates Foundation, the Abby and Howard P. Milstein Program in Chemical Biology and Translational Medicine, the Tri-Institutional TB Research Unit funded by NIAID, NIH (U19 AI111143), grants OPP1024038 and OPP1174780 from the Bill & Melinda Gates Foundation, and the Intramural Research Program of the NIAID, NIH. The WCM Department of Microbiology and Immunology is supported by the William Randolph Hearst Trust."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025